{"ticker": {"uuid": "f4f8b9c5-ff22-40c6-95dd-7bc3c1d636a3", "symbol": "TNYA", "name": "Tenaya Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Tenaya\u2019s new CFO gets options on 1.65M shares, with a $0.8365 exercise price", "summary": "Tenaya Therapeutics (NASDAQ:TNYA) granted stock options to its newly appointed CFO, Eric Hyllengren, for 1.65 million shares, and an additional 187,200 shares to two non-executive employees. These inducement grants, made under the company's 2024 Inducement Equity Incentive Plan, ", "url": "https://www.stocktitan.net/news/TNYA/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-6htvxnio572y.html", "source_name": "Stock Titan", "published_at": "2026-07-15T02:41:46", "published_display": "15 Jul 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics (TNYA) grants CFO 1,650,000 stock options", "summary": "Tenaya Therapeutics (TNYA) granted its Chief Financial Officer, Eric J. Hyllengren, a stock option for 1,650,000 shares of common stock with an exercise price of $0.8365 per share. This option was issued under the 2024 Inducement Equity Incentive Plan, will vest 25% after one yea", "url": "https://www.stocktitan.net/sec-filings/TNYA/form-4-tenaya-therapeutics-inc-insider-trading-activity-3751deac6890.html", "source_name": "Stock Titan", "published_at": "2026-07-15T01:41:46", "published_display": "15 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics (TNYA) CFO files first Form 3 ownership report", "summary": "Tenaya Therapeutics, Inc.'s Chief Financial Officer, Eric J Hyllengren, has filed an initial Form 3 insider ownership report. The filing indicates no buy or sell transactions, no derivative positions, and a neutral net buy/sell status. This Form 3 establishes Hyllengren as an ins", "url": "https://www.stocktitan.net/sec-filings/TNYA/form-3-tenaya-therapeutics-inc-initial-statement-of-beneficial-owners-e5504ec44112.html", "source_name": "Stock Titan", "published_at": "2026-07-15T01:41:46", "published_display": "15 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)", "summary": "Tenaya Therapeutics (NASDAQ: TNYA) announced inducement grants of stock options to its new Chief Financial Officer, Eric Hyllengren, and two other non-executive employees. The grants, totaling 1,650,000 shares for Hyllengren and 187,200 for other employees, were made in accordanc", "url": "https://www.globenewswire.com/news-release/2026/07/15/3327426/0/en/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T00:41:46", "published_display": "15 Jul 2026 00:41", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Piper Sandler reiterates Overweight on Tenaya stock, $40 target", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOcVRVM25qWVBQT1hPSzZjWXF5cjdSaHdOekgzbTdlVjJDQ3VnTkc1cXpqeGpOM200YXNtRDdXZ3J2LVRTVmptVmtIT2dVVW0yYzZTbEpOSlZzN0pkR04xUzF4RVpOWkliNmt0STVTX1NQb1hUNG9VSlNtRUtPRURuRldtMVdWSUVNR08xbnY0Yl9McjhOb2hJalFnbUpaOHlhZ0d6QmF1TmF0WGVfOThTZENIV2FlUnRycEhFcTdB?oc=5", "source_name": "Investing.com", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TNYA - Tenaya Therapeutics Inc Options", "summary": "This article provides a detailed financial overview of Tenaya Therapeutics Inc (TNYA), including its stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. The company closed at $0.7869, showing a 5.50% increase, and has a mark", "url": "https://finviz.com/stock?t=TNYA&ta=1&p=w&ty=oc&b=2&r=y2", "source_name": "Finviz", "published_at": "2026-07-03T19:10:14", "published_display": "03 Jul 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) Path To Profitability", "summary": "Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company, is projected by analysts to reach profitability by 2028, with a forecasted profit of US$121 million after incurring a final loss in 2027. This breakeven projection relies on a very high annual growth", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tnya/tenaya-therapeutics/news/tenaya-therapeutics-incs-nasdaqtnya-path-to-profitability-1", "source_name": "Simply Wall Street", "published_at": "2026-07-03T11:41:06", "published_display": "03 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 78, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics (NASDAQ: TNYA) exits Union City manufacturing lease, shifts to CDMO", "summary": "Tenaya Therapeutics has terminated its lease for the Genetic Medicines Manufacturing Center in Union City, California, originally set to run until July 2031, now ending on August 31, 2026. The company will forfeit a $1.75 million security deposit and pay a termination fee of appr", "url": "https://www.stocktitan.net/sec-filings/TNYA/8-k-tenaya-therapeutics-inc-reports-material-event-13cf13f58482.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:40:15", "published_display": "02 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer", "summary": "Tenaya Therapeutics, a clinical-stage biotechnology company focused on heart disease therapies, announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 13, 2026. He will oversee financial strategy, capital allocation, investor relations, and corpor", "url": "https://investingnews.com/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer/", "source_name": "Investing News Network", "published_at": "2026-06-30T07:40:15", "published_display": "30 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer", "summary": "Tenaya Therapeutics has announced the appointment of Eric Hyllengren as its new Chief Financial Officer. This key leadership addition is expected to bolster the company's financial strategy and operations as it continues to advance its therapeutic pipeline.", "url": "https://www.moomoo.com/news/post/72191390/press-release-tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-29T18:40:57", "published_display": "29 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics Names Eric Hyllengren CFO", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/tenaya-therapeutics-names-eric-hyllengren-130913370.html", "source_name": "MT Newswires", "published_at": "2026-06-29T13:09:13+00:00", "published_display": "29 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eric Hyllengren to lead finances at Tenaya Therapeutics (NASDAQ: TNYA)", "summary": "Tenaya Therapeutics (NASDAQ: TNYA) has appointed Eric Hyllengren as its new Chief Financial Officer, effective July 13, 2026. He will also serve as Principal Financial Officer and Principal Accounting Officer, bringing over two decades of biotech finance experience. His compensat", "url": "https://www.stocktitan.net/sec-filings/TNYA/8-k-tenaya-therapeutics-inc-reports-material-event-3742de27d0c4.html", "source_name": "Stock Titan", "published_at": "2026-06-29T13:12:30", "published_display": "29 Jun 2026 13:12", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics taps biotech finance veteran as CFO", "summary": "Tenaya Therapeutics (NASDAQ:TNYA) has appointed Eric Hyllengren as its new Chief Financial Officer, effective July 13, 2026. Hyllengren brings over 20 years of experience in biotech finance, having previously held CFO roles at Zura Bio and Atara Biotherapeutics, where he secured ", "url": "https://www.stocktitan.net/news/TNYA/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-6nza85s4eo02.html", "source_name": "Stock Titan", "published_at": "2026-06-29T12:12:30", "published_display": "29 Jun 2026 12:12", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Tenaya Therapeutics, Inc. \u2013 NASDAQ:TNYA", "summary": "The article provides a financial data point for Tenaya Therapeutics, Inc. (NASDAQ: TNYA), specifically its forward price to sales ratio. It appears to be a stub or a section from a larger financial data platform like TradingView, given the limited content and extensive navigation", "url": "https://www.tradingview.com/symbols/NASDAQ-TNYA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T05:40:23", "published_display": "27 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Tenaya Therapeutics, Inc. \u2013 NASDAQ:TNYA", "summary": "The article discusses the \"Price to book forward\" metric for Tenaya Therapeutics, Inc. (NASDAQ: TNYA) on TradingView. It appears to be a financial data point without further analysis or specific values presented in the provided content. The surrounding text indicates this is a fi", "url": "https://www.tradingview.com/symbols/NASDAQ-TNYA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T00:41:08", "published_display": "27 Jun 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics Inc (TNYA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Tenaya Therapeutics Inc (TNYA) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and shows no data for past stock splits. The page also includes current stock quotes and ke", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tnya/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T09:10:01", "published_display": "18 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics (TNYA) Jefferies Global Healthcare Conference 2026 Summary", "summary": "Tenaya Therapeutics (TNYA) presented at the Jefferies Global Healthcare Conference 2026, outlining its strategic focus on developing curative therapies for heart disease using gene therapy, small molecules, and gene editing. The company highlighted three clinical-stage programs: ", "url": "https://quartr.com/events/tenaya-therapeutics-tnya-jefferies-global-healthcare-conference-2026_oCBUSCHN", "source_name": "Quartr", "published_at": "2026-06-18T08:10:50", "published_display": "18 Jun 2026 08:10", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics Inc (TNYA) Institutional Confidence", "summary": "This article provides an \"Institutional Confidence\" overview for Tenaya Therapeutics Inc (TNYA), detailing key shareholder activities and holdings. It lists major institutional investors, their share counts, and percentage changes in their holdings. The report is part of a broade", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tnya/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T05:10:01", "published_display": "18 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics Inc (TNYA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article concerns Tenaya Therapeutics Inc's (TNYA) revenue breakdown. It states that relevant data regarding the company's business segments, regional revenue, and profit contribution have not yet been disclosed by the company. As such, the article provides a placeholder for ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tnya/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T22:09:06", "published_display": "17 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Quick Look at Today's Ratings for Tenaya Therapeutics(TNYA.US), With a Forecast Between $2 to $4", "summary": "This article provides a quick overview of analyst ratings for Tenaya Therapeutics (TNYA.US), forecasting a price target range of $2 to $4. It suggests that such analyst coverage can offer insights into the company's potential future performance and investment sentiment.", "url": "https://www.moomoo.com/news/post/71066523/a-quick-look-at-today-s-ratings-for-tenaya-therapeutics", "source_name": "Moomoo", "published_at": "2026-06-05T08:09:59", "published_display": "05 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $2", "summary": "Morgan Stanley has reiterated its \"Buy\" rating for Tenaya Therapeutics (TNYA.US), maintaining a target price of $2. This continued endorsement suggests the firm's confidence in the company's future performance. The maintained rating and price target indicate a consistent positive", "url": "https://www.moomoo.com/news/post/71079780/morgan-stanley-maintains-tenaya-therapeutics-tnyaus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-04T22:40:13", "published_display": "04 Jun 2026 22:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics Announces Interim Data from MyPEAK\u2122-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms", "summary": "Tenaya Therapeutics has released promising interim data from its MyPEAK\u2122-1 clinical trial for TN-201 gene therapy, targeting MYBPC3-associated hypertrophic cardiomyopathy (HCM). The results indicate consistent cardiac remodeling, reductions in symptoms, and improved exercise capa", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tenaya-therapeutics-announces-interim-data-110000266.html", "source_name": "Market source", "published_at": "2026-06-03T23:10:13", "published_display": "03 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics to Announce New Interim Data from MyPEAK-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026", "summary": "Tenaya Therapeutics will present new interim data from Cohort 1 and 2 of its MyPEAK-1 Phase 1b/2 trial for TN-201 gene therapy in adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM) on June 3, 2026. This genetic condition impacts approximately 120,000 patients in the ", "url": "https://investingnews.com/tenaya-therapeutics-to-announce-new-interim-data-from-mypeak-1-phase-1b-2-trial-of-tn-201-for-adults-with-mybpc3-associated-hcm-on-wednesday-june-3-2026/", "source_name": "Investing News Network", "published_at": "2026-06-03T21:39:42", "published_display": "03 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics to Report Interim Data from MyPEAK\u2122-1 Phase 1b/2 Trial of TN-201 Gene Therapy for HCM on June 3, 2026", "summary": "Tenaya Therapeutics will present new interim data from its MyPEAK\u2122-1 Phase 1b/2 trial of TN-201 gene therapy for adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM) on June 3, 2026. This gene therapy aims to deliver a working MYBPC3 gene to heart cells, addressing the", "url": "https://www.quiverquant.com/news/Tenaya+Therapeutics+to+Report+Interim+Data+from+MyPEAK%E2%84%A2-1+Phase+1b%2F2+Trial+of+TN-201+Gene+Therapy+for+HCM+on+June+3,+2026", "source_name": "Quiver Quantitative", "published_at": "2026-06-03T19:39:11", "published_display": "03 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Reports Interim TN-201 Data in MYBPC3-Associated HCM", "summary": "Tenaya Therapeutics' interim phase 1b/2 data for TN-201 gene therapy in MYBPC3-associated hypertrophic cardiomyopathy (HCM) showed promising results. The treatment was well-tolerated and led to improvements in cardiac remodeling, symptom burden, and functional measures in evaluab", "url": "https://www.biopharminternational.com/view/tenaya-reports-interim-tn-201-data-in-mybpc3-associated-hcm", "source_name": "BioPharm International", "published_at": "2026-06-03T12:40:54", "published_display": "03 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics Announces Interim Data from MyPEAK\u2122-1", "summary": "Tenaya Therapeutics reported positive interim safety and efficacy data from its MyPEAK\u2122-1 Phase 1b/2 clinical trial for TN-201, a gene therapy targeting MYBPC3-associated hypertrophic cardiomyopathy (HCM). The data showed improvements in cardiac remodeling, reduced symptoms, and ", "url": "https://www.globenewswire.com/news-release/2026/06/03/3305902/0/en/tenaya-therapeutics-announces-interim-data-from-mypeak-1-showing-treatment-of-mybpc3-associated-hcm-with-tn-201-gene-therapy-resulted-in-consistent-signs-of-cardiac-remodeling-and-.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T11:09:30", "published_display": "03 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gene therapy eases genetic heart condition in small Tenaya trial", "summary": "Tenaya Therapeutics reported positive interim results from its MyPEAK-1 Phase 1b/2 clinical trial for TN-201 gene therapy in MYBPC3-associated hypertrophic cardiomyopathy (HCM). Six evaluable patients showed consistent cardiac remodeling, reductions in left ventricular mass, impr", "url": "https://www.stocktitan.net/news/TNYA/tenaya-therapeutics-announces-interim-data-from-my-peaktm-1-showing-hjn48ennwwmp.html", "source_name": "Stock Titan", "published_at": "2026-06-03T11:09:30", "published_display": "03 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCM - Slideshow (NASDAQ:TNYA)", "summary": "Tenaya Therapeutics (TNYA) discussed interim data from its MyPEAK-1 trial for TN-201, a gene therapy targeting MYBPC3-associated hypertrophic cardiomyopathy (HCM). The company published a slide deck in conjunction with this event, detailing the findings. This update provides insi", "url": "https://seekingalpha.com/article/4911436-tenaya-therapeutics-inc-tnya-discusses-interim-data-from-mypeakminus-1-trial-of-tnminus-201?source=feed_all_articles", "source_name": "Seeking Alpha", "published_at": "2026-06-03T09:52:00", "published_display": "03 Jun 2026 09:52", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics to Announce New Interim Data from MyPEAK\u2122-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tenaya-therapeutics-announce-interim-data-203000206.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T20:30:00+00:00", "published_display": "02 Jun 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya to unveil TN-201 gene therapy HCM trial data June 3, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQemM0c0RESFZpQ0dZOXR5Y2c3ZE5qQUo3VW5SQnFSWVhoOHUzMkhULXg3eXAwYlFNanVIQy1fSFdPSUJjM3VEanFhOWxkc3pkUDdJaEVmbnVwTEhiWjhaSENacFdoV3M4UGh0Yk1HaW5HaFptdmxCU1Bxd1pEZnE2QW53OGxZUndRamZvTWpqOU1OSDZIc3hXZ2hwN2EzUzlzZmVYREgzWEVQcXVpemJhVTRTQXlYUllLZ3QzMg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics (TNYA) director receives 120,000 stock options at $0.7989", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQM2N0cW9ubFByenRDcFlwVnV1Szh2NHNuN1l5elhhNHFRdmZZQjFVV09ZNnpmS0EtZW1sUXVFU2xZam5oLVhsektxQnhwQV9oN2dHSGlHZ3FnUmlBd0plYjJjVjFycExwSHYwNUxOTEJtRGIxbDdlX1pTdXJhbUVkZ2FoVXRPdDJ0X2lUeEsyZ3dfUlQtZnMtZ2hMbTE2X1A1Nko0NXpiY1Y4cVFqaWdJZDllbmpfVFhp?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics to Present at Jefferies Global Healthcare Conference June 2026 | TNYA Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNQ1RVd1RBQnBmdzZvRG10RVU1SXRYbFZfT3ZrdXpjN3lPNkRMb1RMTDRudFpoc3ByRXY4bG5VbC1kTlZmZmxaRlA2VHRzMlAtZVVQY3BvcnpNRFdlWnBGRWlUalZXTjBwVGtYelYyWFJtYlN1T25lMEtXU0haNE50bzcwdHZ5ZUN3SzlDZUJaLUxpSFJBSjMyTXZfeEpQanhKeTA5dkJCQy1OU25fYU54UDd2TXhLZw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOU2NhZXNTaHE1akFMcFoyengwRUZ1eGJrTVB4S1NRTjZ3dFd1QUgxNVJaQVRCcHN3RV91NlpEdG9Tdmh1ekhMdzJDN1ItVU50cHh4Mk9weXR2ZnNCNU5EQ1hGcGtsQlE2Zm0zTzhvRHo1TVN4Uzc3WUxvc1hHMGQxU20tZG5tT0lJR09naTFhdkhFNEtQbmYzWGhMWWEtU1NR?oc=5", "source_name": "Moomoo", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tenaya Therapeutics (TNYA) Is Up 26.6% After New TN-401 Data Near-Term Catalysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxONDBabFNic3ZtR3Z2NlpURXoxemhneHhielZ3cVRfTWZTWVJ0b2swYWtvMEpUeGZIUlVOa2J2a1hKLU9TVGYweHBXMFVuUUttUjVzWGY5eF93eXhNZmc5REw1cmQ1NHpsQWNpSnhrUWhPX3BodEp3SEgtWEVLSGxoWHdLUEE3RnRsR3FWNnVWOVBfX1d3Yng1MTc3VUhmcXJmR0Q2TENhMWl4dlBRSlJyaVRLTFhoWE1HbHg3MjlPTm1iWXFTbHlfcklUenFHb2FTUWNNa09JSnYtRUJ0NHJNOXhIaGk3U3FS0gHuAUFVX3lxTE9ROVhrQWZhNWNMeVhGaEFMUG1uUHllalRQcHFBV29odnE0M2dhdWZfanRSdzdjcGJSeW8yci0wdmYtVzB2MVZfR0loUFpUUFpqQ1R0c1NLV2J5LU1kVjVEVXp5Y3BmdGZCdzNnSURzTWlyaWJ1X08wa3Q5czRWTUtROHJCbWkzSzl6YUx5d3ljZ0l2MzYzSFBYVDdmZ0VscHRpUkhZazAwZXNsOW8wQmZzRTlScHZ6alQ2b0otZlNEZEw4OHAwTXJscUZITWQ0NTBvNDNlOC1QdV9oWmkxTUQ3N09fZTdLSWllczBDdWc?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics (TNYA) Is Up 26.6% After TN-401 Data Buzz and Narrower Losses Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPMm9FUGdlVDVEWDlNblVFT1JMZlowZnM5NU00LVJzWWtKeUtKdi1zMkoxbk9ocjZZVnlLVEkzXzgtVzFtS2ZvSlg4dnhhMlkyeTJFdFhRWGxCQnRlNlRGeEVQMFVaNEFhU1YtQ3g3N3EzcTQxNVNhNk4tSHAxcXZodzdWZU40YjVxU0NjaTNJMzUtTU9RQVctY0pwUlNFeXc?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tenaya Therapeutics (TNYA) Valuation Check As TN-401 Gene Therapy Data Approaches ASGCT 2026", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Tenaya Therapeutics (TNYA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE9kRUJfRFVMaHM0Z1ZaU0x0YzBFSjN5VW52N05EZnlJc3hybXNoaFdpeUV4ZXNrRXQ4eFd6cXRQemhSRkdNY0VWQW04ck1jQnc5LXBTTTRGMlpUWG9UVkQxb0VvVkhISzFXaEZvZQ?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxQc0FaeDNBYk16S0FrZVh5M0pwNS1SaTl6SmN3SjN5WEZFQmpvcS1JaWxOWVdES2dMajMxdVBycThRWGJlSHBnVzhNcUx4bjd4ZXNpMlg0b3FUSS05LUVPdzhIOUM0WWd2czlScXpaWUlBUFl0RUpHR2ZsM2FOMWo0ZEVkbzFYS3RUOEw3akEtNjgyYWtLcEFBcno1VWxtd0hCSmgyNk1WTjl3ZjRvQlJocENQMW5zVW1aZWMwQnZGbWtPbXo0U1FtSFRUZW1QQ21XZlpDc3FuVmNPc0QwdzZKaFJaam1lTkZsZVctOVZ5WVlwbUpqUmItcg?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two heart gene therapy readouts near as Tenaya adds Alnylam deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOWlN3ajNOSzRlZVZ1blVVeEwzU0I2ampHLVU2NHdpa1JWQVdBZThjTFRNTllYWkViYXdhYXlTSUFVZmRES3NpSkJ2Qkt2c1EtVkpJZlRxdkhvR09pdF81bzhCdXMtM09USEV4QTRJYWVIVkp0cXNTN0Y5Yk51LVk4SFlLdnV1TWd5enlWRjZoYTA0TmpLbmJ6amlwUFpYS0ltTVR2VGhzd21pTDlmendhZHpQWHNCNmhVbFJKeEJ4ZXk?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics, Inc. (TNYA) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOSGFiLXNWeFdVZ1N3YWd2R0FsTVo4c2VBcVpQSTdUNzRzM2RrUExPU2Etd2VNcW5YYXJDdXc3ZjdyVVBNZUY2ZHBRNS1GRUZ6MWhZVGtmMkRzV3FzSDVPSXNuUmc5eVpsRkUzLVJNU0tKc2duQW5zUXliNGtaNFlTREtTT3FENGdCSU1rc2RyWXk0a0dWNms5VmEyejhHT1lHNkpXRjJNa1o?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Tenaya Therapeutics (NASDAQ:TNYA) Needs To Drive Business Growth Carefully", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "When Will Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Become Profitable?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPcG5peERDUnRtX1BnemlfenZmdEZmWGo1Qzk5bFM0NnBTOFdpX3A4bjB6dDhVazF0cmxIZy03aXlFUFg5aHpOUXdkT2ZUclNjWE1SLXFNSDZlMnZWTFlDV3o5SlVRRXZSN3JfTVIxcVJ6NzgyT3BKQVFHOHNTNTBvWVYzOUZPbUZXNmlfcVdUZjN0d0otN3BpWVZSUFhLM2pvQ2RsU0l0cw?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "William Blair Analysts Confident on Tenaya Therapeutics (TNYA) Product Pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQX3ZRbHZmSml3WFhCQkM5aWlYS1JaR1Q4MU52a2lSc2NWWmpKWGIxODZ0VTZ1blVCQkYzbUU5ZlRaSnQtM3dvakNtYzYtcnlqODFfVnlOZDk2S2h2cUtMUmlScE1MR2FCdkJBTjVIa3ByZm45cFdjQ1ZqZ1ZxZ1lIWmlrUXFnX1ZUU1VlYjZPcloyVHdrN2pLWnJ3cHhmZUFMbHJNU0o5ZTFyN0FB?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics (TNYA) Is Up 47.7% After Positive TN-301 DMD Data And Alnylam Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPT1VvWDRBU2hjb0oxdFhGRVpmR2lldVVZRkZmNDZLMGpCbGNvVXVuS1F5XzE0N0FjX0FUaWI3MjdkYWxsZ1VUNVZxV0FhLVJnYnZpN2tJNlhfQ0xQUUQwc1p1QzZZY0lxaHFpaVVHdU1oZVhOT2RZdXA1VmxPNFZhaQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQd29ud2w4TFp0Y195dkZtS2tXTVNoendaSnczTTI5RjhwRENNS1F0Vl9nc3Vza28xV0xHZ08tbjh0ZTc3U254UHQtYWkzZGpYYl9zdWdLUlRDVW9PUm0yeWNsTHYtZ2pzSmR1QkVrUUhXOW13b2Mwai1BbXZmZnlwdlY1VlI1eGxEWVZHQTRRbDE5NWZLa3dKUFNoWlRBTTdwU1g0RFlIM1JIenFqWl93UDJoNTRhcUJBU3AxX1RwRFJrY0hCejNLSlRXRWdrSjhp?oc=5", "source_name": "Investing News Network", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Backs Tenaya Therapeutics (TNYA) as SMID-Cap Biotech Primed to Outperform in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPYmdTLWZGOXppNDVwZ1pRVWp5UFozUHM0VWtrMnpIVmUzT2xPVENXRVJkVUpWZm9sZDEtUURCNG5sd285bF9ZMDVlUnhqYnFWMUdjNmR6bEF6eDFTaTdCanJaTUJBamNhZm8tMWpXZ0laZm9ubjN5QW1XTDN1SUo0QnQxM2RlcGhDNEhxLWlJOA?oc=5", "source_name": "Market source", "published_at": "2026-01-19T08:00:00+00:00", "published_display": "19 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Reduces PT on Tenaya Therapeutics (TNYA), Keeps Constructive Stance on U.S. Small- to Mid-Cap Biotech", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxPajF6OHpmUTZjR3lWUF9wcEdBWXNxNDdENFZITkVEQmg0bWY1VFdzcERUX3QtWW1DSEd0OXJMZ2lVTU56b1BadDhGb21UUTNNQ0FRQ2xYLWZmY0VKSks3VGlXNWc5X2tDcnh2MjRzb0x2bWxXYjdzSnlCSjhuRWRPMXVwYkc?oc=5", "source_name": "Market source", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics (TNYA) Is Down 39.7% After Cardiac Gene Therapy Milestones And $60M Fundraise - What's Changed", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxQR3lLZUlBTXBabFkxd1paZC1VZFo5MHhoejhEd1E2UDZoY2EyQnF6M21uVnBscnd4QTJVTEt0V2dqcUVqX2dXb1hWcUktTW1aZjhuRXZNNkVobGFkUUN1Zmh3OV84Nkl0NWxFQ01rVDF3cklydEdyN1VwcjR0UGdZZlc4ZTY?oc=5", "source_name": "Market source", "published_at": "2025-12-14T08:00:00+00:00", "published_display": "14 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With FDA OK to continue gene therapy study, Tenaya raises $60M", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5LNlR3N2lEczR6N2JfbkZFdWlNWHh4LW54SUNxdkdhU0dGaDg5Q21KeTc5VTByam0zMGd4cXVxbVJjX3E1RFJ5emRyWVBWRlA3SmVZ?oc=5", "source_name": "FirstWord PHARMA", "published_at": "2025-12-12T08:00:00+00:00", "published_display": "12 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Tenaya\u2019s new CFO gets options on 1.65M shares, with a $0.8365 exercise price", "summary": "Tenaya Therapeutics (NASDAQ:TNYA) granted stock options to its newly appointed CFO, Eric Hyllengren, for 1.65 million shares, and an additional 187,200 shares to two non-executive employees. These inducement grants, made under the company's 2024 Inducement Equity Incentive Plan, ", "url": "https://www.stocktitan.net/news/TNYA/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-6htvxnio572y.html", "source_name": "Stock Titan", "published_at": "2026-07-15T02:41:46", "published_display": "15 Jul 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics (TNYA) grants CFO 1,650,000 stock options", "summary": "Tenaya Therapeutics (TNYA) granted its Chief Financial Officer, Eric J. Hyllengren, a stock option for 1,650,000 shares of common stock with an exercise price of $0.8365 per share. This option was issued under the 2024 Inducement Equity Incentive Plan, will vest 25% after one yea", "url": "https://www.stocktitan.net/sec-filings/TNYA/form-4-tenaya-therapeutics-inc-insider-trading-activity-3751deac6890.html", "source_name": "Stock Titan", "published_at": "2026-07-15T01:41:46", "published_display": "15 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics (TNYA) CFO files first Form 3 ownership report", "summary": "Tenaya Therapeutics, Inc.'s Chief Financial Officer, Eric J Hyllengren, has filed an initial Form 3 insider ownership report. The filing indicates no buy or sell transactions, no derivative positions, and a neutral net buy/sell status. This Form 3 establishes Hyllengren as an ins", "url": "https://www.stocktitan.net/sec-filings/TNYA/form-3-tenaya-therapeutics-inc-initial-statement-of-beneficial-owners-e5504ec44112.html", "source_name": "Stock Titan", "published_at": "2026-07-15T01:41:46", "published_display": "15 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)", "summary": "Tenaya Therapeutics (NASDAQ: TNYA) announced inducement grants of stock options to its new Chief Financial Officer, Eric Hyllengren, and two other non-executive employees. The grants, totaling 1,650,000 shares for Hyllengren and 187,200 for other employees, were made in accordanc", "url": "https://www.globenewswire.com/news-release/2026/07/15/3327426/0/en/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T00:41:46", "published_display": "15 Jul 2026 00:41", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler reiterates Overweight on Tenaya stock, $40 target", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOcVRVM25qWVBQT1hPSzZjWXF5cjdSaHdOekgzbTdlVjJDQ3VnTkc1cXpqeGpOM200YXNtRDdXZ3J2LVRTVmptVmtIT2dVVW0yYzZTbEpOSlZzN0pkR04xUzF4RVpOWkliNmt0STVTX1NQb1hUNG9VSlNtRUtPRURuRldtMVdWSUVNR08xbnY0Yl9McjhOb2hJalFnbUpaOHlhZ0d6QmF1TmF0WGVfOThTZENIV2FlUnRycEhFcTdB?oc=5", "source_name": "Investing.com", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TNYA - Tenaya Therapeutics Inc Options", "summary": "This article provides a detailed financial overview of Tenaya Therapeutics Inc (TNYA), including its stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. The company closed at $0.7869, showing a 5.50% increase, and has a mark", "url": "https://finviz.com/stock?t=TNYA&ta=1&p=w&ty=oc&b=2&r=y2", "source_name": "Finviz", "published_at": "2026-07-03T19:10:14", "published_display": "03 Jul 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) Path To Profitability", "summary": "Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company, is projected by analysts to reach profitability by 2028, with a forecasted profit of US$121 million after incurring a final loss in 2027. This breakeven projection relies on a very high annual growth", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tnya/tenaya-therapeutics/news/tenaya-therapeutics-incs-nasdaqtnya-path-to-profitability-1", "source_name": "Simply Wall Street", "published_at": "2026-07-03T11:41:06", "published_display": "03 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 78, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics (NASDAQ: TNYA) exits Union City manufacturing lease, shifts to CDMO", "summary": "Tenaya Therapeutics has terminated its lease for the Genetic Medicines Manufacturing Center in Union City, California, originally set to run until July 2031, now ending on August 31, 2026. The company will forfeit a $1.75 million security deposit and pay a termination fee of appr", "url": "https://www.stocktitan.net/sec-filings/TNYA/8-k-tenaya-therapeutics-inc-reports-material-event-13cf13f58482.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:40:15", "published_display": "02 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer", "summary": "Tenaya Therapeutics, a clinical-stage biotechnology company focused on heart disease therapies, announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 13, 2026. He will oversee financial strategy, capital allocation, investor relations, and corpor", "url": "https://investingnews.com/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer/", "source_name": "Investing News Network", "published_at": "2026-06-30T07:40:15", "published_display": "30 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer", "summary": "Tenaya Therapeutics has announced the appointment of Eric Hyllengren as its new Chief Financial Officer. This key leadership addition is expected to bolster the company's financial strategy and operations as it continues to advance its therapeutic pipeline.", "url": "https://www.moomoo.com/news/post/72191390/press-release-tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-29T18:40:57", "published_display": "29 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics Names Eric Hyllengren CFO", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/tenaya-therapeutics-names-eric-hyllengren-130913370.html", "source_name": "MT Newswires", "published_at": "2026-06-29T13:09:13+00:00", "published_display": "29 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eric Hyllengren to lead finances at Tenaya Therapeutics (NASDAQ: TNYA)", "summary": "Tenaya Therapeutics (NASDAQ: TNYA) has appointed Eric Hyllengren as its new Chief Financial Officer, effective July 13, 2026. He will also serve as Principal Financial Officer and Principal Accounting Officer, bringing over two decades of biotech finance experience. His compensat", "url": "https://www.stocktitan.net/sec-filings/TNYA/8-k-tenaya-therapeutics-inc-reports-material-event-3742de27d0c4.html", "source_name": "Stock Titan", "published_at": "2026-06-29T13:12:30", "published_display": "29 Jun 2026 13:12", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics taps biotech finance veteran as CFO", "summary": "Tenaya Therapeutics (NASDAQ:TNYA) has appointed Eric Hyllengren as its new Chief Financial Officer, effective July 13, 2026. Hyllengren brings over 20 years of experience in biotech finance, having previously held CFO roles at Zura Bio and Atara Biotherapeutics, where he secured ", "url": "https://www.stocktitan.net/news/TNYA/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-6nza85s4eo02.html", "source_name": "Stock Titan", "published_at": "2026-06-29T12:12:30", "published_display": "29 Jun 2026 12:12", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Tenaya Therapeutics, Inc. \u2013 NASDAQ:TNYA", "summary": "The article provides a financial data point for Tenaya Therapeutics, Inc. (NASDAQ: TNYA), specifically its forward price to sales ratio. It appears to be a stub or a section from a larger financial data platform like TradingView, given the limited content and extensive navigation", "url": "https://www.tradingview.com/symbols/NASDAQ-TNYA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T05:40:23", "published_display": "27 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Tenaya Therapeutics, Inc. \u2013 NASDAQ:TNYA", "summary": "The article discusses the \"Price to book forward\" metric for Tenaya Therapeutics, Inc. (NASDAQ: TNYA) on TradingView. It appears to be a financial data point without further analysis or specific values presented in the provided content. The surrounding text indicates this is a fi", "url": "https://www.tradingview.com/symbols/NASDAQ-TNYA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T00:41:08", "published_display": "27 Jun 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics Inc (TNYA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Tenaya Therapeutics Inc (TNYA) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and shows no data for past stock splits. The page also includes current stock quotes and ke", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tnya/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T09:10:01", "published_display": "18 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics (TNYA) Jefferies Global Healthcare Conference 2026 Summary", "summary": "Tenaya Therapeutics (TNYA) presented at the Jefferies Global Healthcare Conference 2026, outlining its strategic focus on developing curative therapies for heart disease using gene therapy, small molecules, and gene editing. The company highlighted three clinical-stage programs: ", "url": "https://quartr.com/events/tenaya-therapeutics-tnya-jefferies-global-healthcare-conference-2026_oCBUSCHN", "source_name": "Quartr", "published_at": "2026-06-18T08:10:50", "published_display": "18 Jun 2026 08:10", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics Inc (TNYA) Institutional Confidence", "summary": "This article provides an \"Institutional Confidence\" overview for Tenaya Therapeutics Inc (TNYA), detailing key shareholder activities and holdings. It lists major institutional investors, their share counts, and percentage changes in their holdings. The report is part of a broade", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tnya/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T05:10:01", "published_display": "18 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics Inc (TNYA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article concerns Tenaya Therapeutics Inc's (TNYA) revenue breakdown. It states that relevant data regarding the company's business segments, regional revenue, and profit contribution have not yet been disclosed by the company. As such, the article provides a placeholder for ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tnya/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T22:09:06", "published_display": "17 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Quick Look at Today's Ratings for Tenaya Therapeutics(TNYA.US), With a Forecast Between $2 to $4", "summary": "This article provides a quick overview of analyst ratings for Tenaya Therapeutics (TNYA.US), forecasting a price target range of $2 to $4. It suggests that such analyst coverage can offer insights into the company's potential future performance and investment sentiment.", "url": "https://www.moomoo.com/news/post/71066523/a-quick-look-at-today-s-ratings-for-tenaya-therapeutics", "source_name": "Moomoo", "published_at": "2026-06-05T08:09:59", "published_display": "05 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $2", "summary": "Morgan Stanley has reiterated its \"Buy\" rating for Tenaya Therapeutics (TNYA.US), maintaining a target price of $2. This continued endorsement suggests the firm's confidence in the company's future performance. The maintained rating and price target indicate a consistent positive", "url": "https://www.moomoo.com/news/post/71079780/morgan-stanley-maintains-tenaya-therapeutics-tnyaus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-04T22:40:13", "published_display": "04 Jun 2026 22:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics Announces Interim Data from MyPEAK\u2122-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms", "summary": "Tenaya Therapeutics has released promising interim data from its MyPEAK\u2122-1 clinical trial for TN-201 gene therapy, targeting MYBPC3-associated hypertrophic cardiomyopathy (HCM). The results indicate consistent cardiac remodeling, reductions in symptoms, and improved exercise capa", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tenaya-therapeutics-announces-interim-data-110000266.html", "source_name": "Market source", "published_at": "2026-06-03T23:10:13", "published_display": "03 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics to Announce New Interim Data from MyPEAK-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026", "summary": "Tenaya Therapeutics will present new interim data from Cohort 1 and 2 of its MyPEAK-1 Phase 1b/2 trial for TN-201 gene therapy in adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM) on June 3, 2026. This genetic condition impacts approximately 120,000 patients in the ", "url": "https://investingnews.com/tenaya-therapeutics-to-announce-new-interim-data-from-mypeak-1-phase-1b-2-trial-of-tn-201-for-adults-with-mybpc3-associated-hcm-on-wednesday-june-3-2026/", "source_name": "Investing News Network", "published_at": "2026-06-03T21:39:42", "published_display": "03 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics to Report Interim Data from MyPEAK\u2122-1 Phase 1b/2 Trial of TN-201 Gene Therapy for HCM on June 3, 2026", "summary": "Tenaya Therapeutics will present new interim data from its MyPEAK\u2122-1 Phase 1b/2 trial of TN-201 gene therapy for adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM) on June 3, 2026. This gene therapy aims to deliver a working MYBPC3 gene to heart cells, addressing the", "url": "https://www.quiverquant.com/news/Tenaya+Therapeutics+to+Report+Interim+Data+from+MyPEAK%E2%84%A2-1+Phase+1b%2F2+Trial+of+TN-201+Gene+Therapy+for+HCM+on+June+3,+2026", "source_name": "Quiver Quantitative", "published_at": "2026-06-03T19:39:11", "published_display": "03 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Reports Interim TN-201 Data in MYBPC3-Associated HCM", "summary": "Tenaya Therapeutics' interim phase 1b/2 data for TN-201 gene therapy in MYBPC3-associated hypertrophic cardiomyopathy (HCM) showed promising results. The treatment was well-tolerated and led to improvements in cardiac remodeling, symptom burden, and functional measures in evaluab", "url": "https://www.biopharminternational.com/view/tenaya-reports-interim-tn-201-data-in-mybpc3-associated-hcm", "source_name": "BioPharm International", "published_at": "2026-06-03T12:40:54", "published_display": "03 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics Announces Interim Data from MyPEAK\u2122-1", "summary": "Tenaya Therapeutics reported positive interim safety and efficacy data from its MyPEAK\u2122-1 Phase 1b/2 clinical trial for TN-201, a gene therapy targeting MYBPC3-associated hypertrophic cardiomyopathy (HCM). The data showed improvements in cardiac remodeling, reduced symptoms, and ", "url": "https://www.globenewswire.com/news-release/2026/06/03/3305902/0/en/tenaya-therapeutics-announces-interim-data-from-mypeak-1-showing-treatment-of-mybpc3-associated-hcm-with-tn-201-gene-therapy-resulted-in-consistent-signs-of-cardiac-remodeling-and-.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T11:09:30", "published_display": "03 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gene therapy eases genetic heart condition in small Tenaya trial", "summary": "Tenaya Therapeutics reported positive interim results from its MyPEAK-1 Phase 1b/2 clinical trial for TN-201 gene therapy in MYBPC3-associated hypertrophic cardiomyopathy (HCM). Six evaluable patients showed consistent cardiac remodeling, reductions in left ventricular mass, impr", "url": "https://www.stocktitan.net/news/TNYA/tenaya-therapeutics-announces-interim-data-from-my-peaktm-1-showing-hjn48ennwwmp.html", "source_name": "Stock Titan", "published_at": "2026-06-03T11:09:30", "published_display": "03 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCM - Slideshow (NASDAQ:TNYA)", "summary": "Tenaya Therapeutics (TNYA) discussed interim data from its MyPEAK-1 trial for TN-201, a gene therapy targeting MYBPC3-associated hypertrophic cardiomyopathy (HCM). The company published a slide deck in conjunction with this event, detailing the findings. This update provides insi", "url": "https://seekingalpha.com/article/4911436-tenaya-therapeutics-inc-tnya-discusses-interim-data-from-mypeakminus-1-trial-of-tnminus-201?source=feed_all_articles", "source_name": "Seeking Alpha", "published_at": "2026-06-03T09:52:00", "published_display": "03 Jun 2026 09:52", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics to Announce New Interim Data from MyPEAK\u2122-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tenaya-therapeutics-announce-interim-data-203000206.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T20:30:00+00:00", "published_display": "02 Jun 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya to unveil TN-201 gene therapy HCM trial data June 3, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQemM0c0RESFZpQ0dZOXR5Y2c3ZE5qQUo3VW5SQnFSWVhoOHUzMkhULXg3eXAwYlFNanVIQy1fSFdPSUJjM3VEanFhOWxkc3pkUDdJaEVmbnVwTEhiWjhaSENacFdoV3M4UGh0Yk1HaW5HaFptdmxCU1Bxd1pEZnE2QW53OGxZUndRamZvTWpqOU1OSDZIc3hXZ2hwN2EzUzlzZmVYREgzWEVQcXVpemJhVTRTQXlYUllLZ3QzMg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics (TNYA) director receives 120,000 stock options at $0.7989", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQM2N0cW9ubFByenRDcFlwVnV1Szh2NHNuN1l5elhhNHFRdmZZQjFVV09ZNnpmS0EtZW1sUXVFU2xZam5oLVhsektxQnhwQV9oN2dHSGlHZ3FnUmlBd0plYjJjVjFycExwSHYwNUxOTEJtRGIxbDdlX1pTdXJhbUVkZ2FoVXRPdDJ0X2lUeEsyZ3dfUlQtZnMtZ2hMbTE2X1A1Nko0NXpiY1Y4cVFqaWdJZDllbmpfVFhp?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics to Present at Jefferies Global Healthcare Conference June 2026 | TNYA Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNQ1RVd1RBQnBmdzZvRG10RVU1SXRYbFZfT3ZrdXpjN3lPNkRMb1RMTDRudFpoc3ByRXY4bG5VbC1kTlZmZmxaRlA2VHRzMlAtZVVQY3BvcnpNRFdlWnBGRWlUalZXTjBwVGtYelYyWFJtYlN1T25lMEtXU0haNE50bzcwdHZ5ZUN3SzlDZUJaLUxpSFJBSjMyTXZfeEpQanhKeTA5dkJCQy1OU25fYU54UDd2TXhLZw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOU2NhZXNTaHE1akFMcFoyengwRUZ1eGJrTVB4S1NRTjZ3dFd1QUgxNVJaQVRCcHN3RV91NlpEdG9Tdmh1ekhMdzJDN1ItVU50cHh4Mk9weXR2ZnNCNU5EQ1hGcGtsQlE2Zm0zTzhvRHo1TVN4Uzc3WUxvc1hHMGQxU20tZG5tT0lJR09naTFhdkhFNEtQbmYzWGhMWWEtU1NR?oc=5", "source_name": "Moomoo", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tenaya Therapeutics (TNYA) Is Up 26.6% After New TN-401 Data Near-Term Catalysts", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics (TNYA) Is Up 26.6% After TN-401 Data Buzz and Narrower Losses Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPMm9FUGdlVDVEWDlNblVFT1JMZlowZnM5NU00LVJzWWtKeUtKdi1zMkoxbk9ocjZZVnlLVEkzXzgtVzFtS2ZvSlg4dnhhMlkyeTJFdFhRWGxCQnRlNlRGeEVQMFVaNEFhU1YtQ3g3N3EzcTQxNVNhNk4tSHAxcXZodzdWZU40YjVxU0NjaTNJMzUtTU9RQVctY0pwUlNFeXc?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics (TNYA) Valuation Check As TN-401 Gene Therapy Data Approaches ASGCT 2026", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Tenaya Therapeutics (TNYA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE9kRUJfRFVMaHM0Z1ZaU0x0YzBFSjN5VW52N05EZnlJc3hybXNoaFdpeUV4ZXNrRXQ4eFd6cXRQemhSRkdNY0VWQW04ck1jQnc5LXBTTTRGMlpUWG9UVkQxb0VvVkhISzFXaEZvZQ?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxQc0FaeDNBYk16S0FrZVh5M0pwNS1SaTl6SmN3SjN5WEZFQmpvcS1JaWxOWVdES2dMajMxdVBycThRWGJlSHBnVzhNcUx4bjd4ZXNpMlg0b3FUSS05LUVPdzhIOUM0WWd2czlScXpaWUlBUFl0RUpHR2ZsM2FOMWo0ZEVkbzFYS3RUOEw3akEtNjgyYWtLcEFBcno1VWxtd0hCSmgyNk1WTjl3ZjRvQlJocENQMW5zVW1aZWMwQnZGbWtPbXo0U1FtSFRUZW1QQ21XZlpDc3FuVmNPc0QwdzZKaFJaam1lTkZsZVctOVZ5WVlwbUpqUmItcg?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two heart gene therapy readouts near as Tenaya adds Alnylam deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOWlN3ajNOSzRlZVZ1blVVeEwzU0I2ampHLVU2NHdpa1JWQVdBZThjTFRNTllYWkViYXdhYXlTSUFVZmRES3NpSkJ2Qkt2c1EtVkpJZlRxdkhvR09pdF81bzhCdXMtM09USEV4QTRJYWVIVkp0cXNTN0Y5Yk51LVk4SFlLdnV1TWd5enlWRjZoYTA0TmpLbmJ6amlwUFpYS0ltTVR2VGhzd21pTDlmendhZHpQWHNCNmhVbFJKeEJ4ZXk?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics, Inc. (TNYA) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOSGFiLXNWeFdVZ1N3YWd2R0FsTVo4c2VBcVpQSTdUNzRzM2RrUExPU2Etd2VNcW5YYXJDdXc3ZjdyVVBNZUY2ZHBRNS1GRUZ6MWhZVGtmMkRzV3FzSDVPSXNuUmc5eVpsRkUzLVJNU0tKc2duQW5zUXliNGtaNFlTREtTT3FENGdCSU1rc2RyWXk0a0dWNms5VmEyejhHT1lHNkpXRjJNa1o?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Tenaya Therapeutics (NASDAQ:TNYA) Needs To Drive Business Growth Carefully", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "When Will Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Become Profitable?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPcG5peERDUnRtX1BnemlfenZmdEZmWGo1Qzk5bFM0NnBTOFdpX3A4bjB6dDhVazF0cmxIZy03aXlFUFg5aHpOUXdkT2ZUclNjWE1SLXFNSDZlMnZWTFlDV3o5SlVRRXZSN3JfTVIxcVJ6NzgyT3BKQVFHOHNTNTBvWVYzOUZPbUZXNmlfcVdUZjN0d0otN3BpWVZSUFhLM2pvQ2RsU0l0cw?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "William Blair Analysts Confident on Tenaya Therapeutics (TNYA) Product Pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQX3ZRbHZmSml3WFhCQkM5aWlYS1JaR1Q4MU52a2lSc2NWWmpKWGIxODZ0VTZ1blVCQkYzbUU5ZlRaSnQtM3dvakNtYzYtcnlqODFfVnlOZDk2S2h2cUtMUmlScE1MR2FCdkJBTjVIa3ByZm45cFdjQ1ZqZ1ZxZ1lIWmlrUXFnX1ZUU1VlYjZPcloyVHdrN2pLWnJ3cHhmZUFMbHJNU0o5ZTFyN0FB?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics (TNYA) Is Up 47.7% After Positive TN-301 DMD Data And Alnylam Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPT1VvWDRBU2hjb0oxdFhGRVpmR2lldVVZRkZmNDZLMGpCbGNvVXVuS1F5XzE0N0FjX0FUaWI3MjdkYWxsZ1VUNVZxV0FhLVJnYnZpN2tJNlhfQ0xQUUQwc1p1QzZZY0lxaHFpaVVHdU1oZVhOT2RZdXA1VmxPNFZhaQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQd29ud2w4TFp0Y195dkZtS2tXTVNoendaSnczTTI5RjhwRENNS1F0Vl9nc3Vza28xV0xHZ08tbjh0ZTc3U254UHQtYWkzZGpYYl9zdWdLUlRDVW9PUm0yeWNsTHYtZ2pzSmR1QkVrUUhXOW13b2Mwai1BbXZmZnlwdlY1VlI1eGxEWVZHQTRRbDE5NWZLa3dKUFNoWlRBTTdwU1g0RFlIM1JIenFqWl93UDJoNTRhcUJBU3AxX1RwRFJrY0hCejNLSlRXRWdrSjhp?oc=5", "source_name": "Investing News Network", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Backs Tenaya Therapeutics (TNYA) as SMID-Cap Biotech Primed to Outperform in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPYmdTLWZGOXppNDVwZ1pRVWp5UFozUHM0VWtrMnpIVmUzT2xPVENXRVJkVUpWZm9sZDEtUURCNG5sd285bF9ZMDVlUnhqYnFWMUdjNmR6bEF6eDFTaTdCanJaTUJBamNhZm8tMWpXZ0laZm9ubjN5QW1XTDN1SUo0QnQxM2RlcGhDNEhxLWlJOA?oc=5", "source_name": "Market source", "published_at": "2026-01-19T08:00:00+00:00", "published_display": "19 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Reduces PT on Tenaya Therapeutics (TNYA), Keeps Constructive Stance on U.S. Small- to Mid-Cap Biotech", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxPajF6OHpmUTZjR3lWUF9wcEdBWXNxNDdENFZITkVEQmg0bWY1VFdzcERUX3QtWW1DSEd0OXJMZ2lVTU56b1BadDhGb21UUTNNQ0FRQ2xYLWZmY0VKSks3VGlXNWc5X2tDcnh2MjRzb0x2bWxXYjdzSnlCSjhuRWRPMXVwYkc?oc=5", "source_name": "Market source", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenaya Therapeutics (TNYA) Is Down 39.7% After Cardiac Gene Therapy Milestones And $60M Fundraise - What's Changed", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxQR3lLZUlBTXBabFkxd1paZC1VZFo5MHhoejhEd1E2UDZoY2EyQnF6M21uVnBscnd4QTJVTEt0V2dqcUVqX2dXb1hWcUktTW1aZjhuRXZNNkVobGFkUUN1Zmh3OV84Nkl0NWxFQ01rVDF3cklydEdyN1VwcjR0UGdZZlc4ZTY?oc=5", "source_name": "Market source", "published_at": "2025-12-14T08:00:00+00:00", "published_display": "14 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With FDA OK to continue gene therapy study, Tenaya raises $60M", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5LNlR3N2lEczR6N2JfbkZFdWlNWHh4LW54SUNxdkdhU0dGaDg5Q21KeTc5VTByam0zMGd4cXVxbVJjX3E1RFJ5emRyWVBWRlA3SmVZ?oc=5", "source_name": "FirstWord PHARMA", "published_at": "2025-12-12T08:00:00+00:00", "published_display": "12 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 57, "sentiment_summary": {"positive": 22, "negative": 3, "neutral": 32, "score": 58, "total": 57, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 18.3, "count": 32}, {"event": "earnings", "label": "Earnings", "weight": 7.7, "count": 16}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 22, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 0.87, "latest_week": "2026-07-10", "one_week_move": 10.6, "four_week_move": 22.3, "twelve_week_move": 11.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.338781, "market_dynamics_buy_signal": false, "relative_strength": -24.344077, "fair_value_gap": -58.4, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 38.1306, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+10.6% over one week, +22.3% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 68, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 14}, {"label": "Stock Titan", "count": 10}, {"label": "simplywall.st", "count": 5}, {"label": "GlobeNewswire", "count": 4}, {"label": "Moomoo", "count": 4}, {"label": "Investing News Network", "count": 3}, {"label": "TradingView", "count": 3}, {"label": "TradingKey", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 32}, {"label": "Earnings", "count": 16}, {"label": "Analyst action", "count": 5}, {"label": "Deals and strategy", "count": 2}, {"label": "Capital return", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+10.6% over one week, +22.3% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Tenaya\u2019s new CFO gets options on 1.65M shares, with a $0.8365 exercise price"}], "updated_at": "2026-07-16T05:41:52.937527+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}